More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$82557716
EPS
0.78
P/E ratio
8.3
Price to sales
0.36
Dividend yield
2.769%
Beta
0.296289
Previous close
$6.52
Today's open
$6.55
Day's range
$6.45 - $6.62
52 week range
$5.98 - $27.38
show more
CEO
Steven R. Fife
Employees
222
Headquarters
Lehi, UT
Exchange
NASDAQ Capital Market
Shares outstanding
12701187
Issue type
Common Stock
Consumer Staples
Consumer Products - Healthcare
Should Value Investors Buy Lifevantage (LFVN) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Research • Dec 12, 2025

LifeVantage Corporation (LFVN) Discusses Recovery From Inventory Stockouts and Impact of LoveBiome Acquisition Transcript
LifeVantage Corporation (LFVN) Discusses Recovery From Inventory Stockouts and Impact of LoveBiome Acquisition Transcript
Seeking Alpha • Dec 11, 2025

LifeVantage to Participate in Water Tower Fireside Chat on Thursday, December 11, 2025
SALT LAKE CITY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer, and Carl Aure, Chief Financial Officer, will participate in the upcoming Water Tower Fireside Chat Series on Thursday, December 11, 2025. The webcast of the fireside chat will begin at approximately 2:00 p.m.
GlobeNewsWire • Dec 10, 2025

New Study Finds LifeVantage's P84 Positively Impacts Gut Peptide Production, Activating Key Elements for Comprehensive Gut Health
SALT LAKE CITY, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced new in vitro study results for its proprietary P84 formula revealing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration.* In the controlled, third-party study, targeted gene expression and protein concentration were measured using four gut cell types.
GlobeNewsWire • Nov 12, 2025

Are Investors Undervaluing Lifevantage (LFVN) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Research • Nov 10, 2025

LifeVantage Corporation (LFVN) Q1 2026 Earnings Call Transcript
LifeVantage Corporation ( LFVN ) Q1 2026 Earnings Call November 4, 2025 4:30 PM EST Company Participants Steven Fife - President, CEO & Director Carl Aure - Chief Financial Officer Conference Call Participants Reed Anderson - ICR Inc. Douglas Lane - Water Tower Research LLC Presentation Operator Good afternoon, ladies and gentlemen. Thank you for standing by.
Seeking Alpha • Nov 4, 2025

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2026
SALT LAKE CITY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its first fiscal quarter ended September 30, 2025. First Quarter Fiscal 2026 Summary*: Revenue was $47.6 million, an increase of 0.7% from the prior year period.
GlobeNewsWire • Nov 4, 2025

LifeVantage Declares Quarterly Dividend
SALT LAKE CITY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid December 15, 2025 to all stockholders of record at the close of business on December 1, 2025.
GlobeNewsWire • Nov 4, 2025

Lifevantage (LFVN) Q1 Earnings Top Estimates
Lifevantage (LFVN) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.15 per share a year ago.
Zacks Investment Research • Nov 5, 2025

LifeVantage Empowers Consultants to “Love Life & Drive” at Momentum Academy 2025
SALT LAKE CITY, Oct. 28, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the successful conclusion of Momentum Academy 2025 , a dynamic, high-impact event that brought together thousands of Consultants from across the U.S. from October 23-25 at the Hilton Anatole in Dallas, TX. This year's event centered around the theme: “Love Life & Drive” – inspiring Consultants to take the driver's seat in their businesses with purpose, speed, and unstoppable momentum.
GlobeNewsWire • Oct 28, 2025

¹ Disclosures

Open an M1 investment account to buy and sell Lifevantage Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.